Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (601-610 of 713) with videos related to

Pageof 72
Sort By:
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|January 20, 2015
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cellsLina Han, Peng Qiu, Zhihong Zeng, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 8, 2009
Allogeneic hematopoietic cell transplant for prolymphocytic leukemiaMatt E Kalaycio, Manisha Kukreja, Ann E Woolfrey, et al.
Annals of Hematology|April 29, 2025
Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemiaAnna Turkina, Olga Vinogradova, Elza Lomaia, et al.
American Journal of Hematology|March 31, 2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitorsFadi G Haddad, Koji Sasaki, Ghayas C Issa, et al.
Leukemia & Lymphoma|August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 yearsCatherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.
American Journal of Hematology|July 24, 2013
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemiaAziz Nazha, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia Research|November 9, 2015
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesTalha Badar, Keyur P Patel, Philip A Thompson, et al.
Frontiers in Cardiovascular Medicine|November 4, 2021
Obesity and the Bidirectional Risk of Cancer and Cardiovascular Diseases in African Americans: Disparity vs. AncestryAvirup Guha, Xiaoling Wang, Ryan A Harris, et al.
The New England Journal of Medicine|June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLHagop Kantarjian, Francis Giles, Lydia Wunderle, et al.
Blood|October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateDeborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
Pageof 72

Showing results (601-610 of 713) with videos related to

Sort By:
Pageof 72
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|January 20, 2015
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cellsLina Han, Peng Qiu, Zhihong Zeng, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 8, 2009
Allogeneic hematopoietic cell transplant for prolymphocytic leukemiaMatt E Kalaycio, Manisha Kukreja, Ann E Woolfrey, et al.
Annals of Hematology|April 29, 2025
Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemiaAnna Turkina, Olga Vinogradova, Elza Lomaia, et al.
American Journal of Hematology|March 31, 2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitorsFadi G Haddad, Koji Sasaki, Ghayas C Issa, et al.
Leukemia & Lymphoma|August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 yearsCatherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.
American Journal of Hematology|July 24, 2013
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemiaAziz Nazha, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia Research|November 9, 2015
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesTalha Badar, Keyur P Patel, Philip A Thompson, et al.
Frontiers in Cardiovascular Medicine|November 4, 2021
Obesity and the Bidirectional Risk of Cancer and Cardiovascular Diseases in African Americans: Disparity vs. AncestryAvirup Guha, Xiaoling Wang, Ryan A Harris, et al.
The New England Journal of Medicine|June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLHagop Kantarjian, Francis Giles, Lydia Wunderle, et al.
Blood|October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateDeborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
Pageof 72